Drugs / CD33CART
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05473221 | Aug 2022 → Aug 2024 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT03126864 | Aug 2017 → Oct 2019 | acute myeloid leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03971799 | Jan 2020 → Dec 2029 expected | acute myeloid leukemia | Center for International Blood and Marrow Transplant Research | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03473457 | Apr 2018 → Dec 2020 | acute myeloid leukemia | Zhujiang Hospital | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD33 CAR-T | “one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)” NCT03473457 ↗ |
| Action | Deplete | “We observed potent in vitro cytokine production and cytotoxicity of CD33CARTs incubated with human CD33+ AML cell lines” PMID 34531250 ↗ Sep 2021 |
| Modality | Cell therapy | “Adoptive Cellular Therapy” NCT03126864 ↗ |
| Route | Intravenous | “CD33-CAR-T cell infusion administered by vein on Day 0.” NCT03126864 ↗ |
| Target | CD33 | “CD33 Specific Chimeric Antigen Receptor” NCT03126864 ↗ |